Human Immunology Biosciences (HI-Bio)

Human Immunology Biosciences (HI-Bio) is a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs). Their lead candidate, felzartamab, targets CD38 and is being advanced through clinical trials for multiple indications. HI-Bio also has a pipeline of other candidates targeting cellular drivers of disease.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $95M

Date: 04-Jan-2024

Investors: Alpha Wave Global, Viking Global Investors, Arkin Bio Capital, Jeito Capital, ARCH Venture Partners

Markets: Biotechnology, Immunotherapy, Life Science, Medical, Product Research, Therapeutics

HQ: South San Francisco, California, United States

Founded: 2021

Website: https://hibio.com/

LinkedIn: https://www.linkedin.com/company/hibio

Twitter: https://twitter.com/HIBiosciences

Instagram: